New brain research could reshape our understanding of ADHD and the most common drugs that treat it.

The US FDA has accepted for priority review Otsuka Pharmaceutical’s NDA submitted for centanafadine, an investigational, once-daily extended-release capsule for ADHD treatment.

With an expiration date still more than a year away, here's what the latest details reveal.

From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

The use of medications for Attention-Deficit Hyperactivity Disorder (ADHD) has increased substantially across Europe over the ...

Seoul National University Hospital researchers have linked childhood attention-deficit/hyperactivity disorder and ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...